Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands (original) (raw)

Main

Whole-genome sequencing (WGS) is a powerful tool to understand the transmission dynamics of outbreaks and inform outbreak control decisions4,5,6,7. Evidence of this was seen during the 2014–2016 West African Ebola outbreak when real-time WGS was used to help public health decision-making, a strategy dubbed ‘precision public health pathogen genomics’8,9. Immediate sharing and analysis of data during outbreaks is now recommended as an integral part of outbreak response10,11,12. Feasibility of real-time WGS requires access to sequence platforms that provide reliable sequences, access to metadata for interpretation, and data analysis at high speed and low cost. Therefore, WGS for outbreak support is an active area of research. Nanopore sequencing has been employed in recent outbreaks of Usutu, Ebola, Zika and yellow fever virus owing to the ease of use and relatively low start-up cost4,5,6,7. The robustness of this method has recently been validated using Usutu virus13,[14](/articles/s41591-020-0997-y#ref-CR14 "Oude Munnink, B. B., Nieuwenhuijse, D. F., Sikkema, R. S. & Koopmans, M. Validating whole genome nanopore sequencing, using Usutu virus as an example. J. Vis. Exp. https://doi.org/10.3791/60906

             (2020)."). In the Netherlands, the first COVID-19 case was confirmed on 27 February and WGS was performed in near to real-time using an amplicon-based sequencing approach.

From 22 January, symptomatic travelers from countries where SARS-CoV-2 was known to circulate were routinely tested. The first case of SARS-CoV-2 infection in the Netherlands was identified on 27 February in a person with recent travel history to Italy and an additional case was identified one day later, also in a person with recent travel history to Italy. The genomes of these first two positive samples were generated and analyzed by 29 February. These two viruses clustered differently in the phylogenetic tree, confirming separate introductions (Fig. 1a).

Fig. 1: Phylogenetic analysis of the first two Dutch SARS-CoV-2 sequences.

Fig. 1: Phylogenetic analysis of the first two Dutch SARS-CoV-2 sequences.

The alternative text for this image may have been generated using AI.

Full size image

a,b, All sequences that were publicly available on 29 February (a) or 9 March (b) are included in the analysis. The sequences are colored on the basis of the province of detection. The scale bar represent the amount of nucleotide substitutions per site. Red indicates the Dutch isolates and blue represents SARS-CoV-2 sequences from other countries with recent travel history to Italy.

The advice to test hospitalized patients with serious respiratory infections was issued on 24 February and subsequent attempts to identify possible local transmission chains triggered testing for SARS-CoV-2 on a large scale in hospitals. By 9 March local clusters of epidemiologically related cases of SARS-CoV-2 started to appear in the province of Noord-Brabant. The increase in cases was caused by several co-circulating viruses, and is likely to have been triggered by multiple introductions of the virus following the spring holidays (from 13 to 23 February) with travel to ski resorts in Northern Italy (Fig. 1b). The first intervention was put in place on 9 and 10 March when the prime minister advised people to stop shaking hands and events attended by more than 1,000 visitors were banned in the province of Noord-Brabant. Subsequent analysis identified clusters with local amplification of viruses from patients without any travel history, also outside Noord-Brabant (Fig. 2). This information, combined with the increase in the total number of infections in the Netherlands, led to the decision to implement stricter measures for the whole country to prevent further spread of SARS-CoV-2 on 12 March. All events with more than 100 people attending were canceled, people were requested to work from home as much as possible and people with symptoms such as a fever or cough had to stay at home. On 15 March, this was followed by the closure of schools, catering industries and sport clubs.

Fig. 2: Distribution of SARS-CoV-2 sequences from the Netherlands on 9 and 12 March.

Fig. 2: Distribution of SARS-CoV-2 sequences from the Netherlands on 9 and 12 March.

The alternative text for this image may have been generated using AI.

Full size image

The shapefile for the map is derived from https://gadm.org. The color scale represents the location and the number of whole-genome sequences generated at the indicated time points.

In the third phase, sequencing of new cases with emphasis on health-care workers (HCWs) and hospitalized cases was continued. By 15 March, 189 SARS-CoV-2 viruses from the Netherlands were sequenced, at that moment representing 27.1% of the total number of full genome sequences produced worldwide. The sequences detected in the Netherlands continued to be diverse and revealed the presence of multiple co-circulating sequence types, found in several different clusters in the phylogenetic tree (Fig. 3 and Extended Data Fig. 1). This diversity was also observed in cases with similar travel histories, reflecting that sequence diversity was already present in the originating county, primarily Italy (Fig. 4). In addition to travel-associated cases, an increasing number of local cases was detected through severe acute respiratory infection surveillance; this was not limited to the province Noord-Brabant but SARS-CoV-2 was also increasing in the provinces Zuid-Holland, Noord-Holland and Utrecht, confirming substantial under-ascertainment of the epidemic. The increase in the number of patients with COVID-19 as well as increasing affected geographic areas and occurrence of local clusters provided further support for the increased movement restrictions.

Fig. 3: Phylogenetic analysis of SARS-CoV-2 emergence in the Netherlands.

Fig. 3: Phylogenetic analysis of SARS-CoV-2 emergence in the Netherlands.

The alternative text for this image may have been generated using AI.

Full size image

Zoom-ins of two clusters circulating in the Netherlands. The sequences are colored on the basis of travel history; Dutch patients without travel history are indicated in blue while Dutch patients with travel history to Italy are indicated in red. The scale bars represent the number of substitutions per site.

Fig. 4: BEAST analysis with travel history.

Fig. 4: BEAST analysis with travel history.

The alternative text for this image may have been generated using AI.

Full size image

Time-resolved visualization of the emergence of SARS-CoV-2 in the Netherlands. Sequences from the Netherlands are depicted with big circles. Green indicates recent travel history to Austria, blue to France, yellow to Germany, and red to Italy.

BEAST analysis revealed that the most recent ancestor of the viruses circulating in the Netherlands dates back to the end of January and the beginning of February (Fig. 4). This is in line with the amplification that occurred in the region (notably Italy and Austria) from which most of the epidemic in the Netherlands was seeded. Most incursions likely occurred during spring break, which is a popular time for winter sports vacations. Retrospective testing showed the presence of the virus in a sample collected on 24 February in a patient with known travel history to Italy.

In this study, we show that WGS in combination with epidemiological data strengthened the evidence base for public health decision-making in the Netherlands as it enabled a more precise understanding of the transmission patterns in various initial phases of the outbreaks. As such, we were able to understand the genetic diversity of the multiple introduction events in phase 1, the extent of local and regional clusters in phase 2 and the transmission patterns within the HCW groups in phase 3 (among which the absence or occurrence of very limited nosocomial transmission). This information complemented the data obtained from more traditional methods such as contact investigation.

At the time of the study, sequences from the Netherlands made up a substantial part of the total collection of SARS-CoV-2 genomes. Although implementation of WGS in the Dutch disease prevention and control strategy has shown its added value, there were limitations due to the paucity of genomic information available from certain parts of the world, including Italy. The information available from Iran, another major country where the virus was presumably spreading exponentially in the week before the take-off of the epidemic in the Netherlands, was also limited. This sampling bias needs to be considered when drawing conclusions based on genomic data during early stages of an emerging disease outbreak. Without a representative and sizable selection of reference sequences, reliable phylogenetic analysis is difficult. Clustering and conclusions on the origin of viruses may change substantially when virus sequences of other geographical regions are added to the analysis. Moreover, global monitoring of the genetic diversity of the virus is essential to reliably model and predict the spread of the virus. Since early March, the number of publicly available genomes has grown considerably, and the geographic signature in the dataset is becoming increasingly clear. Since its emergence, the global spread of SARS-CoV-2 led to diversification into lineages that reflect ongoing chains of transmission in specific geographic regions globally, in Europe, and—during the second and third phases—in the Netherlands. The average single nucleotide polymorphism distance between the sequenced viruses in our study was 7.39 and this diversification provided the basis for the use of WGS to investigate possible transmission chains locally (for instance, in health-care settings, where it can be used to inform infection control and prevention when combined with background data on contact histories among others). Moreover, the continued effort will lay the foundation for the enhanced surveillance that will be paramount during the next phase of the pandemic, when confinement measures will gradually be lifted and testing of people with mild symptoms is increased. Given the widespread circulation, the most likely scenario is that SARS-CoV-2 will (sporadically) re-emerge, and discrimination between novel introductions versus prolonged local circulation is important to inform appropriate public health decisions. In addition, owing to genomic mutations, the phenotype and the transmission dynamics of the virus might change over time. Therefore, close monitoring of the behavior of the virus in combination with genetic information is essential as well.

We have used an amplicon-based sequencing approach to monitor the emergence of SARS-CoV-2 in the Netherlands. A critical step in using amplicon-based sequencing is that close, reliable reference sequences need to be available. The primers are designed on the basis of our current knowledge about SARS-CoV-2 diversity and therefore need regular updating. In the future, this may be overcome using metagenomic sequencing. However, at the moment, conventional metagenomic sequencing (Illumina) takes too long for near to real-time sequencing, and nanopore-based metagenomic sequencing is not sensitive enough to allow recovery of whole-genome sequences in a similar fashion and with similar costs compared to amplicon-based nanopore sequencing.

We provide a description of the incursion of SARS-CoV-2 into the Netherlands. The combination of real-time WGS with the data from the National Public Health response team has provided information that helped decide on the next steps in the decision-making. Sharing of metadata is needed within a country but also on a global level. We urge countries to share sequence information to combine our efforts in understanding the spread of SARS-CoV-2. The Global Initiative on Sharing All Influenza Data (GISAID)15,16 made sharing of sequence information coupled to limited metadata possible in a manner that protects the intellectual property and acknowledges the data providers. However, to fully capitalize on the potential added value of WGS for public health decision-making, systems for combined analysis of data are needed that are in agreement with general data protection rules. We previously developed a model for collaborative exploration of WGS and metadata in a protected sharing environment17,[18](/articles/s41591-020-0997-y#ref-CR18 "Covid-19 (European Bioinformatics Institute; accessed 16 April 2020); https://www.ebi.ac.uk/covid-19

            "). For truly global collaboration, such systems would need to be further developed and hosted under the auspices of the WHO (World Health Organization).

Methods

COVID-19 response

This study was carried out in liaison with the national outbreak response team. This team develops guidance on case-finding and containment, based on WHO and European Centre for Disease Prevention and Control recommendations and expert advice, as defined by the crisis and emergency response structure19,20. Diagnostics were initially performed on suspected cases with a recent travel history to China, but between 25 and 28 February also suspected cases with travel history to affected municipalities in Northern Italy were tested. Between 1 and 11 March, all suspected cases with travel history to all four provinces in Northern Italy were tested and after 11 March all suspected cases with travel history to Italy were tested. The sequencing effort was embedded in the stepwise response to the outbreak (Extended Data Fig. 2), which evolved from the initial testing of symptomatic travelers including the testing of symptomatic contacts (phase 1), followed by inclusion of routine testing of patients hospitalized with severe respiratory infections (phase 2), to inclusion of HCWs with a low-threshold case definition and testing to define the extent of suspected clusters (phase 3). Depending on the phase and clinical severity, initial contact with patients was established through public health physicians or nurses from the municipal health service (for travel-related cases, contacts of (hospitalized) cases, and patients belonging to risk groups). The different phases in this study were based on observations described in this manuscript. Ethical approval was not required for this study as only anonymous aggregated data were used, and no medical interventions were made on human individuals.

Contact tracing

On 29 January, COVID-19 was classified as a notifiable disease in group A in the Netherlands, with physicians and laboratories having to report any suspected and confirmed case to the Dutch public health services (PHS) by phone. On notification, the PHS initiates source identification and contact tracing, and performs risk assessments. In the early outbreak phase (containment), the PHS traced and informed all high- and low-risk contacts of cases with the aim to stop further transmission. For each case, epidemiological information such as demographic information, symptoms, date of onset of symptoms, travel history, contact information, suspected source, underlying disease and occupation were registered. People were asked to report their travel history for the past 14 days, including potential travel to several countries. Owing to the magnitude of the COVID-19 outbreak, this quickly became impracticable in severely affected regions, and the strategy shifted to registering only data on confirmed cases and informing their high-risk contacts (phase 2) with continued active case-finding in less affected regions. The PHS informed the national public health authority of the Netherlands (RIVM) about all laboratory-confirmed cases. There, a national case registry was kept in which a contact matrix was kept for the first 250 cases.

Sample selection

In the first phase, all samples were selected for sequencing, reflecting travel-associated cases and their contacts. In the second phase, priority was given to patients identified through enhanced case-finding by testing of hospitalized patients with severe acute respiratory infections and continued sequencing of new incursions. In the third phase, the epidemic started to expand exponentially, and sequencing was performed to continue to monitor the evolution of the outbreak. In line with the national testing policy, a substantial proportion of new cases sequenced were HCWs (20%).

SARS-CoV-2 diagnostics

Clinical specimens were collected and phocine distemper virus was added as an internal nucleic acid (NA) extraction control to the supernatant. Clinical specimens included oropharyngeal and nasopharyngeal swabs, bronchoalveolar lavage and sputum. Total NA was extracted from the supernatant using Roche MagNA Pure systems. The NA was screened for the presence of SARS-CoV-2 using real-time single-plex PCRs with reverse transcription for phocine distemper virus, for the SARS-CoV-2 RdRp gene and for the SARS-CoV-2 E gene as described by Corman et al.21.

SARS-CoV-2 WGS

A SARS-CoV-2-specific multiplex PCR for nanopore sequencing was performed, similar to amplicon-based approaches as previously described22. In short, primers for 89 overlapping amplicons spanning the entire genome were designed using primal (http://primal.zibraproject.org/)22. The amplicon length was set to 500 base pairs with a 75-base-pair overlap between the different amplicons. The used concentrations and primer sequences are shown in Supplementary Table 1. The libraries were generated using the native barcode kits from Nanopore (EXP-NBD104, EXP-NBD114 and SQK-LSK109) and sequenced on a R9.4 flow cell multiplexing up to 24 samples per sequence run.

Sequence data analysis

The resulting raw sequence data were demultiplexed using qcat (https://github.com/nanoporetech/qcat) or Porechop (https://github.com/rrwick/Porechop). Primers were trimmed using cutadapt23, after which a reference-based alignment was performed using minimap224 to the GISAID sequence EPI_ISL_412973. The run was monitored using RAMPART (https://artic-network.github.io/rampart/) and the analysis process was automated using snakemake25, which was used to perform near to real-time analysis with new data every 10 min. The consensus genome was extracted and positions with a coverage <30 were replaced with an ‘N’ with a custom script using biopython and pysam (https://github.com/dnieuw/ENA_SARS_Cov2_nanopore). An overview of the success rate of the sequencing is shown in Supplementary Table 2. Mutations in the genome as compared to the GISAID sequence EPI_ISL_412973 were confirmed by manually checking the alignment. In addition, homopolymeric regions were manually checked and resolved by consulting reference genomes. The average single nucleotide polymorphism difference was determined using snp-dists (https://github.com/tseemann/snp-dists). Human reads were removed by mapping against the human genome (GCF_000001405.26), after which the demultiplexed sequence reads were uploaded to the COVID-19 data portal under the accession numbers ERR4164763–ERR4164952.

Phylogenetic analysis

All available full-length SARS-CoV-2 genomes were retrieved from GISAID on 22 March 2020 (Supplementary Table 3) and aligned with the Dutch SARS-CoV-2 sequences from this study using MUSCLE. Sequences with >10% ‘N’s were excluded. The alignment was manually checked for discrepancies, after which IQ-TREE26 was used to perform a maximum-likelihood phylogenetic analysis under the GTR + F + I + G4 model as the best predicted model using the ultrafast bootstrap option with 1,000 replicates. The phylogenetic trees were visualized using custom python and baltic scripts (https://github.com/evogytis/baltic).

BEAST analysis

All available full-length SARS-CoV-2 genomes were retrieved from GISAID15,16 on 18 March 2020 and downsampled to include only representative sequences from epidemiologically linked cases. Sequences lacking date information were also removed from the dataset. To assess the temporal signal within the data, a maximum-likelihood phylogeny was performed using IQTREE v1.6.827 and the root-to-tip divergence was visualized as a function of sample date using TempEst v1.5.128 (Extended Data Fig. 3). The correlation coefficient for the root-to-tip analysis was 0.53, which is adequate for subsequent Bayesian analysis as much of this noise is accounted for in the Bayesian model. Bayesian phylogenetic trees were estimated using BEAST v1.10.429,30 using an HKY nucleotide substitution model and a strict molecular clock31. The analysis was run for 100,000,000 states with an exponential growth prior. Every 10,000 states, trees and parameters were sampled. Log files were inspected in Tracer v1.7.132 and Tree annotator v1.10.0 was used to remove the burn-in from the tree files and to infer the maximum clade credibility tree. Reported statistics are shown in Supplementary Table 4. Baltic and custom python scripts (https://github.com/evogytis/baltic) were used to visualize the maximum clade credibility tree.

Reporting Summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The data produced in this study are available on the COVID-19 data portal under the accession numbers ERR4164763–ERR4164952 and on the GISAID portal under the accession numbers EPI_ISL_413564– EPI_ISL_413591, EPI_ISL_414423– EPI_ISL_414471, EPI_ISL_414529– EPI_ISL_414566 and EPI_ISL_415460–EPI_ISL_415535.

Change history

A Correction to this paper has been published: https://doi.org/10.1038/s41591-020-1128-5

References

  1. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
    CAS PubMed PubMed Central Google Scholar
  2. Gorbalenya, A. E. et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
    Article Google Scholar
  3. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).
    Article CAS PubMed PubMed Central Google Scholar
  4. Oude Munnink, B. B. et al. Genomic monitoring to understand the emergence and spread of Usutu virus in the Netherlands, 2016–2018. Sci. Rep. 10, 2798 (2020).
    Article PubMed PubMed Central Google Scholar
  5. Quick, J. et al. Real-time, portable genome sequencing for Ebola surveillance. Nature 530, 228–232 (2016).
    Article CAS PubMed PubMed Central Google Scholar
  6. Faria, N. R. et al. Zika virus in the Americas: early epidemiological and genetic findings. Science 352, 345–349 (2016).
    Article CAS PubMed PubMed Central Google Scholar
  7. Faria, N. R. et al. Genomic and epidemiological monitoring of yellow fever virus transmission potential. Science 361, 894–899 (2018).
    Article CAS PubMed PubMed Central Google Scholar
  8. Khoury, M. J. et al. From public health genomics to precision public health: a 20-year journey. Genet. Med. 20, 574–582 (2018).
    Article PubMed Google Scholar
  9. Armstrong, G. L. et al. Pathogen genomics in public health. N. Engl. J. Med. 381, 2569–2580 (2019).
    Article PubMed PubMed Central Google Scholar
  10. Polonsky, J. A. et al. Outbreak analytics: a developing data science for informing the response to emerging pathogens. Philos. Trans. R. Soc. B 374, 20180276 (2019).
    Article Google Scholar
  11. Gire, S. K. et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345, 1369–1372 (2014).
    CAS PubMed PubMed Central Google Scholar
  12. Modjarrad, K. et al. Developing global norms for sharing data and results during public health emergencies. PLoS Med. 13, e1001935 (2016).
    Article PubMed PubMed Central Google Scholar
  13. Oude Munnink, B. B. et al. Towards high quality real-time whole genome sequencing during outbreaks using Usutu virus as example. Infect. Genet. Evol. 73, 49–54 (2019).
    Article CAS PubMed Google Scholar
  14. Oude Munnink, B. B., Nieuwenhuijse, D. F., Sikkema, R. S. & Koopmans, M. Validating whole genome nanopore sequencing, using Usutu virus as an example. J. Vis. Exp. https://doi.org/10.3791/60906 (2020).
  15. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob. Chall. 1, 33–46 (2017).
    Article PubMed PubMed Central Google Scholar
  16. Shu, Y. & McCauley, J. GISAID: Global Initiative on Sharing All Influenza Data—from vision to reality. Eurosurveillance 22, 30494 (2017).
    Article PubMed PubMed Central Google Scholar
  17. Amid, C., Pakseresht, N. & Silvester, N. The COMPARE data hubs. Database 2019, baz136 (2019).
    Article PubMed PubMed Central Google Scholar
  18. Covid-19 (European Bioinformatics Institute; accessed 16 April 2020); https://www.ebi.ac.uk/covid-19
  19. Kraaij – Dirkzwager, M. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014. Eurosurveillance 19, 20817 (2014).
    Article PubMed Google Scholar
  20. Timen, A. Response to imported case of Marburg hemorrhagic fever, the Netherlands. Emerg. Infect. Dis. 15, 1171–1175 (2009).
    Article PubMed PubMed Central Google Scholar
  21. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25, 2000045 (2020).
    PubMed Central Google Scholar
  22. Quick, J. et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat. Protoc. 12, 1261–1276 (2017).
    Article CAS PubMed PubMed Central Google Scholar
  23. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 17, 10–12 (2011).
    Article Google Scholar
  24. Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094–3100 (2018).
    Article CAS PubMed PubMed Central Google Scholar
  25. Köster, J. & Rahmann, S. Snakemake—a scalable bioinformatics workflow engine. Bioinformatics 28, 2520–2522 (2012).
    Article PubMed Google Scholar
  26. Nguyen, L. T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268–274 (2015).
    Article CAS PubMed Google Scholar
  27. Quang, B. et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol. Biol. Evol. 37, 1530–1534 (2020).
  28. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen). Virus Evol. 2, vew007 (2016).
    Article PubMed PubMed Central Google Scholar
  29. Ayres, D. L. et al. BEAGLE: an application programming interface and high-performance computing library for statistical phylogenetics. Syst. Biol. 61, 170–173 (2012).
    Article PubMed Google Scholar
  30. Suchard, M. A. et al. Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol. 4, vey016 (2018).
    Article PubMed PubMed Central Google Scholar
  31. Hasegawa, M., Kishino, H. & Yano, T. Dating of the human–ape splitting by a molecular clock of mitochondrial DNA. J. Mol. Evol. 22, 160–174 (1985).
    Article CAS PubMed Google Scholar
  32. Rambaut, A., Drummond, A. J., Xie, D., Baele, G. & Suchard, M. A. Posterior summarization in Bayesian phylogenetics using Tracer 1.7. Syst. Biol. 67, 901–904 (2018).
    Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank the following additional members of the Dutch-Covid-19 response team: staff of the Department of Communicable Disease Control, Public Health Service Amsterdam, MHC Amsterdam, Amsterdam; staff of the Department of Communicable Disease Control, Public Health Service Gelderland-Zuid, MHC Gelderland-Zuid, Tiel; the Laboratorium Medische Microbiologie of JBZ, MHC Hart voor Brabant, Tilburg; staff of the Department of Communicable Disease Control, Public Health Service Utrecht, MHC Regio Utrecht, Utrecht; staff of the Department of Communicable Disease Control, Public Health Service Rotterdam-Rijnmond, MHC Rotterdam-Rijnmond, Rotterdam; staff of the Department of Communicable Disease Control, Public Health Service Zaanstreek-Waterland, MHC Zaanstreek Waterland, Zaandam; staff of the Department of Communicable Disease Control, Public Health Service Brabant Zuidoost, MHC Brabant Zuidoost, Eindhoven. We gratefully acknowledge the originating laboratories, where specimens were first obtained, and the submitting laboratories, where sequence data were generated and submitted to the EpiFlu Database of the GISAID, on which this research is based. All contributors of data may be contacted directly via the GISAID website (http://platform.gisaid.org). We also acknowledge M. de Graaf for her expertise in the interpretation of the early phylogenetic analysis. B.B.O.M., R.S.S., D.F.N., R.M. and M.K. received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement numbers 874735 (VEO), 848096 (SHARP JA) and 101003589 (RECoVER) and C.S., B.B.O.M. and M.K. from the European Joint Programme One Health EJP under the grant agreement number 773830 (METASTAVA). Part of this work was funded by the NIAID/NIH contract HHSN272201400008C for T.B., P.L. and M.P.

Author information

Author notes

  1. These authors contributed equally: Aura Timen, Marion Koopmans.

Authors and Affiliations

  1. ErasmusMC, Department of Viroscience, WHO Collaborating Centre for Arbovirus and Viral Hemorrhagic Fever Reference and Research, Rotterdam, the Netherlands
    Bas B. Oude Munnink, David F. Nieuwenhuijse, Claudia Schapendonk, Mark Pronk, Pascal Lexmond, Anne van der Linden, Theo Bestebroer, Irina Chestakova, Ronald J. Overmars, Stefan van Nieuwkoop, Richard Molenkamp, Annemiek A. van der Eijk, Corine GeurtsvanKessel, Reina S. Sikkema & Marion Koopmans
  2. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
    Mart Stein, Manon Haverkate, Madelief Mollers, Sandra K. Kamga, Harry Vennema, Adam Meijer, Jaap van Dissel & Aura Timen
  3. Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK
    Áine O’Toole & Andrew Rambaut
  4. Academic Hospital Maastricht, Maastricht, the Netherlands
    G. J. A. P. M. Oudehuis
  5. Amsterdam Medical Centre, Amsterdam, the Netherlands
    Janke Schinkel
  6. Amphia Hospital, Breda, the Netherlands
    Jan Kluytmans, Marjolein Kluytmans-van den Bergh, Wouter van den Bijllaardt, Robbert G. Berntvelsen & Miranda M. L. van Rijen
  7. Bernhoven Hospital, Uden, the Netherlands
    Jan Kluytmans, Marjolein Kluytmans-van den Bergh, Jaco J. Verweij & Anton G. N. Buiting
  8. Bravis Ziekenhuis, Bergen op Zoom & Roosendaal, Roosendaal, the Netherlands
    Peter Schneeberger
  9. Dienst Gezondheid & Jeugd Zuid-Holland Zuid, Dordrecht, the Netherlands
    Suzan Pas, Bram M. Diederen & Anneke M. C. Bergmans
  10. Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands
    P. A. Verspui van der Eijk
  11. RLM, Dordecht, the Netherlands
    Roel Streefkerk
  12. Foundation PAMM, Eindhoven, the Netherlands
    A. P. Aldenkamp
  13. Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands
    P. de Man, J. G. M. Koelemal, D. Ong, S. Paltansing & N. Veassen
  14. MHC Gooi & Vechtstreek, Bussum, the Netherlands
    Jacqueline Sleven
  15. MHC Haaglanden, The Hague, the Netherlands
    Leendert Bakker & Heinrich Brockhoff
  16. MHC Hart voor Brabant, Tilburg, the Netherlands
    Ariene Rietveld
  17. MHC Holland Noorden, Alkmaar, the Netherlands
    Fred Slijkerman Megelink & James Cohen Stuart
  18. MHC Kennemerland, Haarlem, the Netherlands
    Anne de Vries, Wil van der Reijden & A. Ros
  19. MHC West-Brabant, Breda, the Netherlands
    Esther Lodder
  20. MHC Zuid-Holland Zuid, Dordrecht, the Netherlands
    Ellen Verspui-van der Eijk & Inge Huijskens
  21. Ijsselland Hospital, Capelle aan den IJssel, the Netherlands
    E. M. Kraan & M. P. M. van der Linden
  22. Isala Hospital, Zwolle, the Netherlands
    S. B. Debast
  23. Laboratorium Microbiologie Twente Achterhoek, Hengelo, the Netherlands
    N. Al Naiemi
  24. Leids Universitair Medisch Centrum, Leiden, the Netherlands
    A. C. M. Kroes
  25. Maasstad Hospital, Rotterdam, the Netherlands
    Marjolein Damen, Sander Dinant, Sybren Lekkerkerk, Oscar Pontesilli, Pieter Smit & Carla van Tienen
  26. Meander Medical Centre, Amersfoort, the Netherlands
    P. C. R. Godschalk
  27. MHC Drente, Meppel, the Netherlands
    Jorien van Pelt & Alewijn Ott
  28. MHC Flevoland, Lelystad, the Netherlands
    Charlie van der Weijden
  29. Radboud University Medical Center, Nijmegen, the Netherlands
    Heiman Wertheim & Janette Rahamat-Langendoen
  30. Centre for Infectious Disease Control, Bilthoven, the Netherlands
    Johan Reimerink, Rogier Bodewes, Erwin Duizer, Bas van der Veer & Chantal Reusken
  31. Foundation Jeroen Bosch Hospital’s, Hertogenbosch, the Netherlands
    Suzanne Lutgens, Peter Schneeberger, Mirjam Hermans, P. Wever & A. Leenders
  32. Nursing Home Maastricht, Maastricht, the Netherlands
    Henriette ter Waarbeek & Christian Hoebe

Authors

  1. Bas B. Oude Munnink
  2. David F. Nieuwenhuijse
  3. Mart Stein
  4. Áine O’Toole
  5. Manon Haverkate
  6. Madelief Mollers
  7. Sandra K. Kamga
  8. Claudia Schapendonk
  9. Mark Pronk
  10. Pascal Lexmond
  11. Anne van der Linden
  12. Theo Bestebroer
  13. Irina Chestakova
  14. Ronald J. Overmars
  15. Stefan van Nieuwkoop
  16. Richard Molenkamp
  17. Annemiek A. van der Eijk
  18. Corine GeurtsvanKessel
  19. Harry Vennema
  20. Adam Meijer
  21. Andrew Rambaut
  22. Jaap van Dissel
  23. Reina S. Sikkema
  24. Aura Timen
  25. Marion Koopmans

Consortia

The Dutch-Covid-19 response team

Contributions

B.B.O.M., R.S.S., Á.O’T. and M.K. wrote the manuscript, Á.O’T., M.S., M.H. and M.M. set up sample and data collection, B.B.O.M, A.v.d.L., I.C., M.P., P.L., S.v.N., T.B., C.S. and R.J.O generated sequence data, S.K.K., R.M., A.A.v.d.E. and C.G. were involved in sample and data collection, B.B.O.M., R.R.S., D.F.N., A.R., A.M., H.V., A.O., Á.O’T., J.v.D. and M.K. were involved in data analysis and interpretation, B.B.O.M., M.S., M.H., M.M., R.R.S., Á.O’T. and M.K. designed the study. All authors provided critical feedback.

Corresponding author

Correspondence toMarion Koopmans.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Jennifer Sargent was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

Rights and permissions

About this article

Cite this article

Oude Munnink, B.B., Nieuwenhuijse, D.F., Stein, M. et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands.Nat Med 26, 1405–1410 (2020). https://doi.org/10.1038/s41591-020-0997-y

Download citation